Mebendazole as Adjuvant Treatment for Colon Cancer

NCT03925662 — Phase 3, Recruiting, 40 participants, Sherief Abd-Elsalam
ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

Clinical Study Evaluating Mebendazole as Adjuvant Therapy in Patients With Colorectal Cancer

RegistryNCT03925662
StatusRecruiting
PhasePhase 3
Study typeInterventional; randomized, parallel, masking: none, treatment
Enrollment40 (Estimated)
SponsorSherief Abd-Elsalam (Other)
ConditionsColorectal Cancer
InterventionsFolfox with avastin, Mebendazole (Drug)
Datesstart 2019-04-01, primary completion 2028-12-01 (estimated), completion 2028-12-01 (estimated), first posted 2019-04-24, last updated 2019-04-24
Locations1 site in Egypt

Related Papers Related Patents Related Grants Related Experts
All trials for Colorectal Cancer All trials of Folfox with avastin All trials of Mebendazole

-Summary

mebendazole treating colon cancer

Expand all sections  ·  Collapse all

+Detailed description

mebendazole as adjuvant treatment for colon cancer

+Arms and interventions

ArmTypeInterventionsDescription
Folfox with avastinActive comparatorDrug: Folfox with avastinFolfox with avastin only
MebendazoleExperimentalDrug: MebendazoleFolfox with avastin with mebendazole
  • Folfox with avastin (Drug), also known as folfox 4: Folfox with avastin only
  • Mebendazole (Drug), also known as mebendazol: Folfox with avastin with mebendazole

+Outcome measures

Primary outcomes

  • number of patients with tumour response [6 months]: number of patients with response

+Eligibility

Sex: All, ages: 18 Years to any

Inclusion Criteria:

* Colorectal cancer stage 4.

Exclusion Criteria:

* Agranulocytosis
* Pregnancy
* Allergy to mebendazole.

+Locations (1)

FacilityCityCountryStatus
Sherief Abd-ElsalamCairoEgyptRecruiting

+Publications

  • Results publication: Hegazy SK, El-Azab GA, Zakaria F, Mostafa MF, El-Ghoneimy RA. Mebendazole; from an anti-parasitic drug to a promising candidate for drug repurposing in colorectal cancer. Life Sci. 2022 Jun 15;299:120536. doi: 10.1016/j.lfs.2022.120536. Epub 2022 Apr 3. PMID 35385794

+Investigators